Dr. Wayne Batchelor currently serves as the Director or Interventional Cardiology, Director of Interventional Cardiology Research, Innovation and Education and Associate Director of the Inova Heart and Vascular Institute in Fairfax, VA. He is also an Adjunct Professor of Medicine at Duke University. Dr. Batchelor’s clinical and research interests span a broad range of complex structural heart and percutaneous coronary interventions (PCI), including transcatheter mitral valve repair/replacement, transcatheter aortic valve replacement (TAVR), percutaneous left atrial appendage closure and ASD/PFO closure. He has published over 200 peer-reviewed original abstracts/manuscripts, multiple book chapters and has participated in over 160 clinical trials, including serving as Principal Investigator in over 50 and has served on several national/international clinical trial steering committees. He recently served as National Co-Principal Investigator of the PLATINUM Diversity study, the first and only study to prospectively evaluate clinical outcomes in 1,501 minorities and women after coronary stent procedures across 52 U.S. sites and is currently National PI of the ALERT trial, a randomized trial evaluating the effectiveness of cardiac intelligence software in detecting undertreated aortic stenosis. Dr. Batchelor holds several leadership positions within national and international professional societies, including Chair of the American College of Cardiology’s (ACC) Interventional Sectional Leadership Council, Co-Chair of the NCDR STS/TVT Registry’s Steering Committee, Program Committee Member for the 2023 ACC/World Congress of Cardiology Scientific Sessions, and is a lifetime member of the Association of Black Cardiologists. He serves on the editorial boards of the Journal of the Society of Cardiovascular Angiography and Interventions and Cardiovascular Revascularization Medicine journals and has served as Guest-Editor on Journal of the American College of Cardiology. He is a special government employee and consultant to the U.S. Food and Drug Administration (FDA) within the Cardiovascular Devices Branch.